Phase 2 N=21 A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis
Primary Axillary Hyperhidrosis
Primary: The Number of Participants With Treatment Emergent Adverse Events (All TEAEs). — 5; 5; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=350 Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)
Axillary Hyperhidrosis
Primary: Number of Participants (Vehicle Arm vs. Sofpironium Bromide Gel, 15%) With and Without an Observed ≥2-point Improvement in Hyperhidrosis Disease Severity…
Phase 3 N=300 A Safety Study of BBI-4000 Gel in Patients With Axillary Hyperhidrosis
Primary Axillary Hyperhidrosis
Primary: The Number of Participants With Treatment Emergent Adverse Events Cumulative to Week 48 by Maximum Severity — 27; 55; 29; 58 Participants
Phase 3 N=351 Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-302)
Axillary Hyperhidrosis
Primary: Number of Participants (Vehicle Arm vs. Sofpironium Bromide Gel, 15%) With and Without an Observed ≥2-point Improvement in Hyperhidrosis Disease Severity…
Phase 2 N=39 Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis
Hyperhidrosis
Primary: Mean Plasma Concentration After Repeat Dosing of Umeclidinium — 33.09; 29.86; 41.22; 42.72 picogram per millilitre (pg/ml)
N/A N=120 Evaluation of N-SWEAT Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating
Primary Axillary Hyperhidrosis
Primary: Safety of the N-SWEAT Patch — 14; 4 Participants
Phase 3 N=152 GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis
Hyperhidrosis
Primary: Percentage of Responders Assessed by Gravimetric Measurement at Week 4 in the First Treatment Phase — 96.2; 45.9 percentage of participants — p=<0.001
Phase 2 N=58 A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects
Hyperhidrosis
Primary: Posterior Probability That the Response Rate is Greater Than 50% — 1; 0.9997 Posterior Probability
Phase 3 N=564 Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis
Hyperhidrosis
Primary: Long-term Safety Assessed Through Adverse Events and Local Skin Reactions — 148; 153; 28; 120 Adverse Events and Local Skin Reactions
Phase 2 N=145 Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis
Hyperhidrosis
Primary: Percentage of Participants With Both a Change From Baseline in Hyperhidrosis Disease Severity Scale (HDSS) Score by ≥ 2 Points and a Change From Baseline in Gravimetric…
Phase 2 N=198 A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis
Hyperhidrosis
Primary: Percentage of Subjects Who Have a Minimum 2-grade Improvement in HDSS From Baseline at Week 4 — 14; 20; 21; 18 Participants
Phase 2 N=189 A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
Hyperhidrosis
Primary: Proportion of Subjects Achieving at Least 2-point Decrease in Hyperhidrosis Disease Severity Scale (HDSS) From Baseline to Week 4 — 35; 37; 29; 36 Participants
N/A N=20 Evaluation of the Ulthera System for Treating Axillary Hyperhidrosis
Axillary Hyperhidrosis
Primary: Number of Participants With Hyperhidrosis Disease Severity Scale (HDSS) Score Reduction at Day 30 Post Second Treatment — 11 participants
N/A N=17 Evaluation of 1440nm Laser vs. Botulinum Toxin or miraDry® Microwave For Treatment of Axillary Hyperhidrosis
Hyperhidrosis
Primary: Change in Sweating Assessed Using Gravimetry — 267.91; 57.36; 155.14 mg
Phase 2 N=227 A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
Hyperhidrosis
Primary: Change of Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax) Score From Baseline to End of Therapy — -1.30; -2.02; -2.09; -2.10 score on a scale